Real-time insights. Smarter decisions. Better trades.
🔍 Search StocksConfidence: 75.00%
Date: 08-05-2026
Price: $3.190
Last Price: $2.860
Post-Signal Low Price: $2.730
Most readers would already know that AFT Pharmaceuticals' (NZSE:AFT) stock increased by 9.7% over the past three months. Given its impressive performance, we decided to study the company's key financial indicators as a company's long-term fundamentals usually dictate market outcomes. Particularly, w
Key Insights The projected fair value for AFT Pharmaceuticals is NZ$3.31 based on 2 Stage Free Cash Flow to Equity Current share price of NZ$3.80 suggests AFT Pharmaceuticals is potentially trading close to its fair value Our fair value estimate is 21% lower than AFT Pharmaceuticals' analyst price
Key Insights Significant insider control over AFT Pharmaceuticals implies vested interests in company growth 70% of the company is held by a single shareholder (Hartley Atkinson) Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a compan
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses is one path to excess returns. For example, long term AFT Pharmaceuticals Limited (NZSE:AFT) shareholders have enjoyed a 40% share price rise over the last half decade, well in exces
Most readers would already know that AFT Pharmaceuticals' (NZSE:AFT) stock increased by 1.6% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to AFT Pharmaceuticals' ROE to
AI Confidence - 75.00 % model confidence
AFT Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development, marketing, and distribution of branded pharmaceutical products primarily in New Zealand, Australia, and selected international markets. The company holds a strong market position in over-the-counter and prescription medicines, leveraging a diversified product portfolio and expanding global footprint in Asia-Pacific regions.
| Cash Flow | Moderate |
| Debt | Low |
| Profitability | Moderate |
| Revenue Trend | Flat |
| Trend | Bearish |
| Momentum | Weak |
| RSI Signal | Neutral |
| Support Level | $ 3.00 |
| Resistance Level | $ 3.50 |